Lexaria Bioscience (LEXX) Profit After Tax (2017 - 2026)

Lexaria Bioscience has disclosed Profit After Tax across 10 years of filings, most recently posting -$1.5 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$1.5 million, up 46.53% year-over-year; the trailing twelve-month figure through Feb 2026 was -$9.5 million (down 1.41% YoY), and the FY2025 annual result was -$11.9 million, down 104.9% from the prior year.
• Profit After Tax came in at -$1.5 million for Q1 2026 at Lexaria Bioscience, up from -$1.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$649539.0 in Q1 2024 to a low of -$3.8 million in Q2 2025.
• The 5-year median for Profit After Tax is -$1.8 million (2022), against an average of -$1.9 million.
• Across the five-year window, Profit After Tax tumbled 462.62% in 2022 and jumped 49.96% in 2024, its largest moves.
• Lexaria Bioscience's Profit After Tax stood at -$1.8 million in 2022, then jumped by 32.84% to -$1.2 million in 2023, then plunged by 129.26% to -$2.7 million in 2024, then surged by 41.01% to -$1.6 million in 2025, then climbed by 8.92% to -$1.5 million in 2026.
• The last three Profit After Tax figures came in at -$1.5 million (Q1 2026), -$1.6 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.